-
Aerocrine AB: Primary care trial supports FeNO-guided asthma treatment
SOLNA, Sweden — Aerocrine AB, a medical products company focused on improved management and care of patients with such inflammatory airway diseases as asthma, has announced that a new randomized clinical trial shows lower incidence of asthma exacerbations and increased asthma control with Fractional exhaled Nitric Oxide (FeNO)-guided anti-inflammatory treatment.
The study has been published on theweb site of the Journal of Allergy and Clinical Immunology: In Practice.